Milbemycin A3 oxime is an anthelmintic, a derivative of milbemycin A3 , and a component of milbemycin oxide . It reduces the number of microfilariae of the heartworm D. immitis in the blood of naturally infested dogs by 85.2% when administered at a dose of 0.05 mg/kg. Formulations containing milbemycin A3 oxime, in combination with milbemycin A4 oxime, have been used in the treatment of parasitic infections in dogs.
Milbemycin A3 oxime is the minor component of the anti-parasitic product milbemycin oxime.
Milbemycin A3 oxime is a semi-synthetic macrocyclic lactone prepared by the oxidation and oximation of a mixture of milbemycin A3. Milbemycin A3 oxime is the minor component (~30%) in the commercial product milbemycin oxime, marketed for endo- and exo-parasite infections. Like the other milbemycin/avermectins, milbemycin A3 oxime acts by opening glutamate sensitive chloride channels in neurons of invertebrates leading to paralysis by hyperpolarisation of these cells and signal transfer blocking.
